Smoking status and vascular risk factors as predictors of disability in AQP4-NMOSD and MOGAD.

IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Multiple Sclerosis Journal Pub Date : 2025-05-01 Epub Date: 2025-03-15 DOI:10.1177/13524585251325069
Fiona Chan, David Berhanu, Sara Samadzadeh, Anna Francis, Nasrin Asgari, Friedemann Paul, M Isabel Leite, Ruth Geraldes, Jacqueline Palace
{"title":"Smoking status and vascular risk factors as predictors of disability in AQP4-NMOSD and MOGAD.","authors":"Fiona Chan, David Berhanu, Sara Samadzadeh, Anna Francis, Nasrin Asgari, Friedemann Paul, M Isabel Leite, Ruth Geraldes, Jacqueline Palace","doi":"10.1177/13524585251325069","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Smoking and vascular risk factors (VRFs) are reported to have adverse effects in multiple sclerosis but data are limited in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD). This study aimed to measure their impact on disability.</p><p><strong>Methods: </strong>Smoking status was defined as never, past or current smokers and VRF comprised of ⩾1: hypertension, dyslipidemia, high body mass index or diabetes. Logistic regression models were fitted to predict their influence on recovery from <i>onset</i> attack and <i>first optic neuritis (ON)</i> attack.</p><p><strong>Results: </strong>A total of 442 patients were included. Current MOGAD smokers had a higher risk of disability from onset attack and first ON attack than never smokers (odds ratio (OR) 2.9, 95% confidence interval (CI) 1.3-6.9; OR 3.3, 95% CI 1.4-7.8). VRF in MOGAD was not predictive of disability. Current AQP4-NMOSD smokers and VRFs had a higher risk of residual disability from onset attacks (OR 7.5, 95% CI 2.1-27.7; OR 1.9, 95% CI 1.0-3.4). VRF was associated with higher risk of visual disability (OR 2.6, 95% CI 1.08-6.46) while smoking status was not.</p><p><strong>Conclusions: </strong>Current smoking status detrimentally influenced onset attack recovery in AQP4-NMOSD and MOGAD patients, including visual recovery in MOGAD. Non-smoking VRFs influenced clinical and visual outcomes in AQP4-NMOSD.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"658-667"},"PeriodicalIF":5.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092943/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585251325069","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Smoking and vascular risk factors (VRFs) are reported to have adverse effects in multiple sclerosis but data are limited in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD). This study aimed to measure their impact on disability.

Methods: Smoking status was defined as never, past or current smokers and VRF comprised of ⩾1: hypertension, dyslipidemia, high body mass index or diabetes. Logistic regression models were fitted to predict their influence on recovery from onset attack and first optic neuritis (ON) attack.

Results: A total of 442 patients were included. Current MOGAD smokers had a higher risk of disability from onset attack and first ON attack than never smokers (odds ratio (OR) 2.9, 95% confidence interval (CI) 1.3-6.9; OR 3.3, 95% CI 1.4-7.8). VRF in MOGAD was not predictive of disability. Current AQP4-NMOSD smokers and VRFs had a higher risk of residual disability from onset attacks (OR 7.5, 95% CI 2.1-27.7; OR 1.9, 95% CI 1.0-3.4). VRF was associated with higher risk of visual disability (OR 2.6, 95% CI 1.08-6.46) while smoking status was not.

Conclusions: Current smoking status detrimentally influenced onset attack recovery in AQP4-NMOSD and MOGAD patients, including visual recovery in MOGAD. Non-smoking VRFs influenced clinical and visual outcomes in AQP4-NMOSD.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
吸烟状况和血管危险因素作为AQP4-NMOSD和MOGAD致残的预测因素。
背景:据报道,吸烟和血管危险因素(vrf)在多发性硬化症中有不良影响,但在水通道蛋白-4抗体阳性的视神经脊髓炎谱系障碍(AQP4-NMOSD)和髓鞘少梢胶质细胞糖蛋白抗体病(MOGAD)中数据有限。这项研究旨在衡量它们对残疾的影响。方法:吸烟状态被定义为从未、过去或当前吸烟者,并且VRF由大于或等于1组成:高血压、血脂异常、高体重指数或糖尿病。拟合Logistic回归模型预测其对首发发作和首次视神经炎(on)发作恢复的影响。结果:共纳入442例患者。目前MOGAD吸烟者因发病和首次ON发作致残的风险高于从不吸烟者(优势比(OR) 2.9, 95%可信区间(CI) 1.3-6.9;或3.3,95% ci 1.4-7.8)。MOGAD患者的VRF不能预测残疾。目前AQP4-NMOSD吸烟者和vrf患者的发病残障风险更高(OR 7.5, 95% CI 2.1-27.7;或1.9,95% ci 1.0-3.4)。VRF与更高的视力障碍风险相关(OR 2.6, 95% CI 1.08-6.46),而吸烟状态无关。结论:吸烟状况不利于AQP4-NMOSD和MOGAD患者的起病发作恢复,包括MOGAD患者的视力恢复。非吸烟vrf影响AQP4-NMOSD的临床和视觉结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Multiple Sclerosis Journal
Multiple Sclerosis Journal 医学-临床神经学
CiteScore
10.90
自引率
6.90%
发文量
186
审稿时长
3-8 weeks
期刊介绍: Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585
期刊最新文献
Baló's concentric sclerosis successfully treated with alemtuzumab: Long-term follow-up. A first report of progressive multifocal leukoencephalopathy in childhood-onset NMOSD. Treating Balo's concentric sclerosis in the monoclonal antibody era. Navigating the uncharted-Progressive multifocal leukoencephalopathy in a child with NMOSD treated with rituximab. Acute retinal necrosis associated with dimethyl fumarate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1